Latest 10-Q quarterly reports

Kartoon Studios reported a 24% decrease in total revenue for Q1 2026 compared to the prior year, primarily driven by a significant drop in production services, while content distribution saw a notable increase.

Agape ATP Corporation reported a decrease in revenue for the first quarter of 2026, primarily driven by a strategic shift away from its network marketing business.

Mobile Global Esports Inc. reported its first quarter 2026 financial results, showing initial revenue generation and increased operating expenses.

HeartCore Enterprises reported a significant revenue decrease in Q1 2026, primarily due to challenges in its customized software development and services segment, alongside a substantial drop in gross profit margin.

QVC, Inc. reports a net loss of $16 million for the first quarter of 2026, with total revenue down 7.1% year-over-year, as the company navigates Chapter 11 bankruptcy proceedings.

Neuphoria Therapeutics Inc. reported a net loss for the quarter ended March 31, 2026, and is undergoing a strategic review, pausing its PTSD program.

QVC Group, Inc. has filed for voluntary reorganization under Chapter 11 of the U.S. Bankruptcy Code, citing significant debt obligations and a restructuring support agreement.

Instil Bio's Q1 2026 Form 10-Q filing reveals a net loss of $4.2 million, a significant reduction from the prior year, alongside strategic shifts and ongoing liquidity concerns.

First Seacoast Bancorp, Inc. reported a reduced net loss for the first quarter of 2026, driven by improved net interest income and non-interest income, despite a slight decrease in total assets.

SecureTech Innovations reports significant revenue growth in Q1 2026 driven by the AI UltraProd acquisition, alongside ongoing efforts to strengthen internal controls and pursue strategic market expansion.

LM Funding America, Inc. reported a net loss of $10.1 million for the first quarter of 2026, a significant increase from the prior year's loss, driven by a substantial fair market adjustment on digital assets and increased operating expenses.

Pioneer Acquisition I Corp reports net income of $1.99 million for Q1 2026, primarily driven by interest income from its trust account, while continuing its search for a business combination.

Cocrystal Pharma reported a net loss of $2.3 million for Q1 2026, with cash reserves projected to last less than 12 months, while advancing its antiviral drug candidates.

Zapata Quantum, Inc. filed its Q1 2026 10-Q, detailing a net loss of $1.31 million and a significant decrease in cash, while also announcing a $15 million capital raise in April 2026.

NexPoint Diversified Real Estate Trust reported a net loss of $21.3 million for Q1 2026, with revenues decreasing to $22.9 million.

Pulmatrix, Inc. reported its Q1 2026 results, detailing a proposed merger with Eos SENOLYTIX, Inc. and concurrent private financings totaling $19 million.

Harte Hanks reports a 10.3% revenue decrease in Q1 2026, leading to a wider net loss and lower operating income across key segments.

AirJoule Technologies Corporation reported a net loss of $49.8 million for Q1 2026, impacted by a substantial $110.3 million impairment of in-process R&D and $76.1 million goodwill impairment within its AirJoule JV with GE Vernova.

Venu Holding Corporation reported an 11% increase in total revenues for Q1 2026, driven by restaurant sales, but also saw a significant rise in operating costs and a wider net loss.

Indaptus Therapeutics reports a significant decrease in R&D expenses and a net loss for Q1 2026, while exploring strategic transaction opportunities.

60 Degrees Pharmaceuticals reported a slight decrease in product revenue for Q1 2026, alongside increased operating expenses, while continuing to focus on its infectious disease pipeline and managing its cash position.

BioCardia, Inc. reported its first quarter 2026 financial results, highlighting ongoing development of its cell therapies and progress with regulatory bodies, while facing significant cash burn and Nasdaq listing concerns.

Enveric Biosciences reports Q1 2026 results, highlighting progress on lead candidate EB-003 and a recent capital raise, while addressing ongoing liquidity concerns.

Nuvera Communications saw a significant increase in net income and operating income in Q1 2026, driven by strong data service growth, despite declines in voice and video revenues.

AVAX One Technology Ltd. reported a significant increase in revenue for Q1 2026, driven by its Avalanche Protocol and Bitcoin Mining operations, despite substantial unrealized losses on digital asset valuations.

VerifyMe, Inc. reported a significant 60% decrease in net revenue for Q1 2026 compared to the prior year, primarily due to the termination of its ProActive services agreement with a major carrier partner.

Our Bond Inc. reported a 4.36% increase in revenue for Q1 2026, reaching $2.347 million, but also a significant widening of its net loss to $6.703 million.

GT Biopharma reports a wider net loss for Q1 2026 compared to the prior year, driven by increased selling, general, and administrative expenses, while research and development costs decreased.

Creative Realities, Inc. reported a net loss of $7.46 million for Q1 2026, with total sales increasing 68% to $16.35 million, largely driven by the acquisition of CDM.

Rein Therapeutics reports progress on LTI-03 Phase 2 trial and significant capital raise, aiming to extend runway into Q1 2028.